OMEROS CORP (OMER) Fundamental Analysis & Valuation

NASDAQ:OMER • US6821431029

Current stock price

11.665 USD
-0.25 (-2.06%)
Last:

This OMER fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. OMER Profitability Analysis

1.1 Basic Checks

  • In the past year OMER has reported negative net income.
  • In the past year OMER has reported a negative cash flow from operations.
  • In multiple years OMER reported negative net income over the last 5 years.
  • OMER had negative operating cash flow in 4 of the past 5 years.
OMER Yearly Net Income VS EBIT VS OCF VS FCFOMER Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • OMER has a better Return On Assets (-1.03%) than 77.60% of its industry peers.
Industry RankSector Rank
ROA -1.03%
ROE N/A
ROIC N/A
ROA(3y)-26.59%
ROA(5y)-21.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OMER Yearly ROA, ROE, ROICOMER Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K 1.5K

1.3 Margins

  • OMER does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OMER Yearly Profit, Operating, Gross MarginsOMER Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. OMER Health Analysis

2.1 Basic Checks

  • OMER has more shares outstanding than it did 1 year ago.
  • OMER has more shares outstanding than it did 5 years ago.
  • OMER has a better debt/assets ratio than last year.
OMER Yearly Shares OutstandingOMER Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
OMER Yearly Total Debt VS Total AssetsOMER Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of -3.51, we must say that OMER is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of OMER (-3.51) is worse than 61.46% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.51
ROIC/WACCN/A
WACCN/A
OMER Yearly LT Debt VS Equity VS FCFOMER Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 2.76 indicates that OMER has no problem at all paying its short term obligations.
  • OMER has a Current ratio (2.76) which is in line with its industry peers.
  • OMER has a Quick Ratio of 2.76. This indicates that OMER is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of OMER (2.76) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.76
Quick Ratio 2.76
OMER Yearly Current Assets VS Current LiabilitesOMER Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. OMER Growth Analysis

3.1 Past

  • OMER shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.48%, which is quite impressive.
EPS 1Y (TTM)81.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%281.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • OMER is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 73.38% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-149.7%
EPS Next 2Y3.69%
EPS Next 3Y54.88%
EPS Next 5Y73.38%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OMER Yearly Revenue VS EstimatesOMER Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
OMER Yearly EPS VS EstimatesOMER Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

1

4. OMER Valuation Analysis

4.1 Price/Earnings Ratio

  • OMER reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year OMER is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OMER Price Earnings VS Forward Price EarningsOMER Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OMER Per share dataOMER EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2

4.3 Compensation for Growth

  • OMER's earnings are expected to grow with 54.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.69%
EPS Next 3Y54.88%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. OMER Dividend Analysis

5.1 Amount

  • No dividends for OMER!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

OMER Fundamentals: All Metrics, Ratios and Statistics

OMEROS CORP

NASDAQ:OMER (4/10/2026, 3:00:07 PM)

11.665

-0.25 (-2.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-31
Earnings (Next)05-13
Inst Owners47.2%
Inst Owner Change0%
Ins Owners2.78%
Ins Owner Change-29.19%
Market Cap839.88M
Revenue(TTM)N/A
Net Income(TTM)-3.35M
Analysts80
Price Target44.54 (281.83%)
Short Float %25.12%
Short Ratio16.46
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)132.51%
Min EPS beat(2)-3.55%
Max EPS beat(2)268.56%
EPS beat(4)2
Avg EPS beat(4)69.26%
Min EPS beat(4)-3.55%
Max EPS beat(4)268.56%
EPS beat(8)5
Avg EPS beat(8)42.61%
EPS beat(12)8
Avg EPS beat(12)35.21%
EPS beat(16)12
Avg EPS beat(16)61.34%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)29.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-2.07
FCFYN/A
OCF(TTM)-2.07
OCFYN/A
SpS0
BVpS-1.68
TBVpS-1.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.03%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.59%
ROA(5y)-21.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.37%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.76
Quick Ratio 2.76
Altman-Z -3.51
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)25.18%
Cap/Depr(5y)22.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%281.48%
EPS Next Y-149.7%
EPS Next 2Y3.69%
EPS Next 3Y54.88%
EPS Next 5Y73.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year75.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-300.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-299.13%
OCF growth 3YN/A
OCF growth 5YN/A

OMEROS CORP / OMER Fundamental Analysis FAQ

What is the ChartMill fundamental rating of OMEROS CORP (OMER) stock?

ChartMill assigns a fundamental rating of 2 / 10 to OMER.


What is the valuation status of OMEROS CORP (OMER) stock?

ChartMill assigns a valuation rating of 1 / 10 to OMEROS CORP (OMER). This can be considered as Overvalued.


How profitable is OMEROS CORP (OMER) stock?

OMEROS CORP (OMER) has a profitability rating of 1 / 10.


Can you provide the financial health for OMER stock?

The financial health rating of OMEROS CORP (OMER) is 3 / 10.